BioSyent (CVE:RX) Share Price Passes Below Fifty Day Moving Average – Should You Sell?

BioSyent Inc. (CVE:RX)’s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$11.26 and traded as low as C$11.03. BioSyent shares last traded at C$11.05, with a volume of 2,810 shares changing hands.

BioSyent Price Performance

The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. The company’s 50 day moving average price is C$11.26 and its 200-day moving average price is C$10.97. The company has a market cap of C$128.07 million, a price-to-earnings ratio of 18.42 and a beta of 0.93.

Insiders Place Their Bets

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total value of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of BioSyent stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total transaction of C$55,628.75. Over the last 90 days, insiders have sold 349,144 shares of company stock worth $3,903,370. 33.65% of the stock is owned by insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.